- Home
- CANF vs SRFM Comparison
CANF vs SRFM Comparison
Compare CANF & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SRFM
- Stock Information
- Founded
- CANF 1994
- SRFM 2011
- Country
- CANF Israel
- SRFM United States
- Employees
- CANF N/A
- SRFM N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SRFM Transportation Services
- Sector
- CANF Health Care
- SRFM Consumer Discretionary
- Exchange
- CANF Nasdaq
- SRFM Nasdaq
- Market Cap
- CANF 14.8M
- SRFM 58.2M
- IPO Year
- CANF N/A
- SRFM 2023
- Fundamental
- Price
- CANF $1.02
- SRFM $3.95
- Analyst Decision
- CANF Strong Buy
- SRFM Buy
- Analyst Count
- CANF 2
- SRFM 4
- Target Price
- CANF $14.00
- SRFM $5.56
- AVG Volume (30 Days)
- CANF 146.1K
- SRFM 13.7M
- Earning Date
- CANF 08-29-2025
- SRFM 08-13-2025
- Dividend Yield
- CANF N/A
- SRFM N/A
- EPS Growth
- CANF N/A
- SRFM N/A
- EPS
- CANF N/A
- SRFM N/A
- Revenue
- CANF $674,000.00
- SRFM $112,307,000.00
- Revenue This Year
- CANF $461.72
- SRFM N/A
- Revenue Next Year
- CANF N/A
- SRFM $54.32
- P/E Ratio
- CANF N/A
- SRFM N/A
- Revenue Growth
- CANF N/A
- SRFM 31.17
- 52 Week Low
- CANF $0.98
- SRFM $0.90
- 52 Week High
- CANF $4.69
- SRFM $6.72
- Technical
- Relative Strength Index (RSI)
- CANF 39.13
- SRFM 64.64
- Support Level
- CANF $0.99
- SRFM $3.30
- Resistance Level
- CANF $1.09
- SRFM $4.16
- Average True Range (ATR)
- CANF 0.04
- SRFM 0.79
- MACD
- CANF -0.00
- SRFM 0.17
- Stochastic Oscillator
- CANF 16.67
- SRFM 61.32
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.